Healthcare / BiotechnologyNasdaqCM
$0.98
+0.03 (+2.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 12%
FCF escenarios
weak_data · normalized FCF $-43.6M · quality 21.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$31M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1099.3%
↓Gross Margin
N/A
•Debt/Equity
5.17
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
-68.7%
FCF CAGR
—
FCF margin
-198363.6%
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22000.0 · net income $-61.4M · FCF $-43.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $22000.00 | $22000.00 | — | $2.0M | $3.3M | $2.3M |
| Net Income | $-61.4M | $-61.4M | $-52.8M | $-71.1M | $-58.2M | $-55.3M |
| EBITDA | $-60.1M | $-60.1M | $-56.9M | $-61.3M | $-58.2M | — |
| EPS | -2.73 | -2.73 | -12.03 | -16.01 | -22.30 | -190.00 |
| Operating Margin | -289668.2% | -289668.2% | — | -3375.4% | -1889.3% | -1765.4% |
| Net Margin | -279263.6% | -279263.6% | — | -3592.4% | -1771.5% | -2414.6% |
| Balance Sheet | ||||||
| Debt/Equity | 5.17 | 5.17 | 1.31 | 0.56 | 0.29 | — |
| Cash Flow | ||||||
| Free Cash Flow | $-43.6M | $-43.6M | $-41.4M | $-64.4M | $-76.3M | $-40.2M |
| Returns | ||||||
| ROE | -1099.3% | -1099.3% | -205.8% | -106.2% | -45.7% | 49.6% |
| Valuation | ||||||
| P/B | 3.94 | 3.94 | 0.77 | 0.40 | 0.32 | — |
| Growth & Yield | ||||||
| Revenue Growth | — | — | — | -39.8% | — | — |
| EPS Growth | 77.3% | 77.3% | 24.9% | 28.2% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-68.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-12.03 → -2.73
Residual
-68.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.